tirzepatide and autoimmune disease GLP-1 Agonists in Shifting the Scales: Tirzepatide's Breakthrough

Since tirzepatide also promotes lower blood sugar, the combination requires monitoring for hypoglycemia

Limited data exists for: Understudied Populations: Adults over 75 years (increased sensitivity to appetite suppression) Adolescents (ongoing development considerations) Individuals with BMI under 27 (insufficient safety data) Pregnant or lactating individuals (no safety data) Individuals with significant psychiatric conditions Gender Considerations: Research suggests some metabolic peptides may show differential effects between males and females, though data for cagrilintide and retatrutide specifically remains limited

The most common reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, reflux, gas, bloating, and injection site irritation

Some patients report better sleep after weight and sugar control